Archives
-
HNF4A-AS1, Lipid Reprogramming, and Sorafenib Resistance
2026-08-20
A 2024 Theranostics study identifies the liver-enriched lncRNA HNF4A-AS1 as a suppressor of sorafenib resistance in hepatocellular carcinoma. Its central contribution is a mechanistic link between HNF4A-AS1, METTL3-dependent m6A modification of DECR1 mRNA, PUFA abundance, and ferroptosis sensitivity.
-
2-NBDG Glucose Uptake Assay Kit: Lab Guide
2026-08-19
A scenario-based guide to using the 2-NBDG Glucose Uptake Assay Kit, SKU K2212, for non-radioactive glucose uptake measurements in viability, cytotoxicity, and metabolic studies. It explains assay principles, controls, interpretation limits, protocol standardization, and practical product-selection criteria.
-
EZ Cap™ Human PTEN mRNA: Assay Design
2026-08-19
Learn how EZ Cap™ Human PTEN mRNA supports mechanistic cancer research through Cap 1-mediated translation, poly(A)-tail stabilization, and PTEN pathway rescue. This guide translates recent PTEN mRNA delivery findings into practical assay-selection and interpretation strategies.
-
HNF4A-AS1, Lipid Metabolism, and Sorafenib Resistance
2026-08-18
The 2024 Theranostics study identifies liver-enriched lncRNA HNF4A-AS1 as a suppressor of sorafenib resistance in hepatocellular carcinoma by regulating PUFA availability and ferroptosis. Its mechanistic model links HNF4A-AS1 to METTL3-dependent m6A modification of DECR1 mRNA, providing a framework for connecting RNA regulation with lipid metabolic adaptation in therapy-resistant HCC.
-
Novobiocin Activity Against Resistant Staphylococci
2026-08-18
The reference study directly compared mupirocin and Novobiocin susceptibility in meticillin-susceptible and meticillin-resistant staphylococci recovered from healthy dogs and dogs with superficial pyoderma. Its main contribution is a clinically relevant susceptibility framework showing that resistance phenotype and disease context can substantially influence in vitro activity, particularly for Novobiocin.
-
BH3 Mimetics Clear Senescent Breast Cancer Cells
2026-08-17
Shahbandi and colleagues showed that chemotherapy-induced senescent breast cancer cells can acquire a delayed, selective dependence on antiapoptotic BCL-2 family proteins. In TP53 wild-type models, sequential treatment with chemotherapy followed by ABT-263, with MCL1 inhibition when required, promoted tumor regression and extended survival in mice.
-
Thiazovivin: Practical ROCK Inhibitor Guidance
2026-08-17
Thiazovivin is a ROCK inhibitor used to support fibroblast reprogramming and improve human embryonic stem cell survival after trypsinization. This article provides dossier-based handling and workflow guidance for in vitro stem cell research; it is not a substitute for a validated protocol and is not intended for diagnostic, therapeutic, or clinical use.
-
Tranexamic Acid Workflows for Fibrinolysis Research
2026-08-16
Build reproducible plasmin, clot-stability, cell-adhesion, and wound-material assays with Tranexamic Acid, an antifibrinolytic agent that targets lysine-dependent fibrin interactions. The workflow connects concentration-controlled bench experiments to a bi-layer dressing strategy that combines clot stabilization with antibacterial functionality.
-
Cytochalasin B: From Actin Mechanism to Translation
2026-08-15
Cytochalasin B, also known as NSC 107658, is more than an actin-disrupting reagent: it is a mechanistic probe for testing how cytoskeletal dynamics govern cell entry, motility, division, and translationally relevant phenotypes. This thought-leadership perspective connects actin biology with host-pathogen research, assay design, and drug discovery strategy.
-
Selective Hypothermic Albumin Perfusion in Stroke
2026-08-14
A 2026 study reports that intra-arterial selective cooling human serum albumin infusion provides stronger protection against cerebral ischemia–reperfusion injury than cooling saline or albumin-only comparators in a rat MCAO model. The findings connect improved neurological recovery with reduced neuroinflammation and preservation of the blood–brain barrier through suppression of the ROCK1/MLC–F-actin pathway.
-
METTL16–SENP3–LTF Axis Drives HCC Ferroptosis Resistance
2026-08-14
Wang et al. identify a METTL16–SENP3–LTF regulatory axis that protects hepatocellular carcinoma cells from iron-dependent lipid peroxidation and promotes tumor progression. The study combines m6A-focused molecular assays, organoids, xenografts, genetically engineered mice, and human samples to connect RNA modification with iron handling and ferroptosis sensitivity.
-
Anisomycin Workflows for JNK Activation
2026-08-13
Anisomycin offers a controllable way to activate JNK for apoptosis, cancer-cell stress, and pathway-validation experiments. This workflow also explains how to use it cautiously alongside the neuroligin 1 proteolysis mechanism reported in social memory research without treating an exploratory neuroscience application as established evidence.
-
Propranolol Workflows for Translational Research
2026-08-13
Build reproducible cardiovascular, neurobehavioral, and metabolic assays with Propranolol, a non-selective β-adrenergic receptor blocker. This guide combines practical dosing, stock-preparation controls, cross-domain assay design, and pharmacogenomics-aware troubleshooting.
-
Lipidated Nanophotosensitizer Blocks Tumor Metastasis
2026-08-12
This Nature Cancer study introduces a lipidated nanophotosensitizer that traces tumor extracellular vesicles (TEVs) and generates reactive oxygen species inside both tumor cells and TEVs. The dual-localization strategy suppressed primary tumors and TEV-mediated metastatic communication in multiple preclinical mouse models, offering a selective alternative to broadly inhibiting extracellular-vesicle biogenesis.
-
25-Hydroxycholesterol Reprograms Tumor Macrophages
2026-08-12
Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal lipid sensing to AMPKα–STAT6 signaling and ARG1 production in tumor-associated macrophages. The study also shows that disrupting CH25H can improve T-cell-mediated tumor control and enhance responses to anti-PD-1 therapy.